Silo Pharma, Inc. (Nasdaq: SILO) ('Silo” or 'the Company), a diversified developmental-stage biopharmaceutical and ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and ...

The application follows guidance provided to IMUNON in Pre-IND meeting with the FDA LAWRENCEVILLE, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage ...

Milestone payment reflects continued progress under strategic research collaboration addressing high-need patient ...

Investigational New Drug (IND) application submitted to the U.S. Food and Drug administration (FDA) Plans in place to initiate a Human clinical trial in 60 healthy volunteers in the USA Clinical Trial ...

YONGIN, South Korea, Sept. 22, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a leading South Korean pharmaceutical company, announced today that it has submitted an Investigational New Drug (IND) ...

SYX-5219 is a first-in-class oral PKM2 modulator designed to drive sustained disease remission across a range of autoimmune diseases Phase 1b trial to investigate the safety, tolerability and initial ...

In preclinical studies, VYN202 achieved consistent reductions in pro-inflammatory and disease-related biomarkers and improvements in disease severity across a variety of inflammatory and fibrotic ...